Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5
|
作者：
Cao, Yi [1 ,2 ]
Li, Yunjin [1 ,2 ]
Liu, Ruijie [1 ]
Zhou, Jianhua [1 ,2 ]
Wang, Kuansong [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China
来源：
CANCERS | 2023年 / 15卷 / 09期
基金：
中国国家自然科学基金;
关键词：
HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;
D O I：
10.3390/cancers15092568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.
引用
收藏
页数：27
相关论文
共 50 条
  • [41] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [42] Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
    Vernieri, Claudio
    Milano, Monica
    Brambilla, Marta
    Mennitto, Alessia
    Maggi, Claudia
    Cona, Maria Silvia
    Prisciandaro, Michele
    Fabbroni, Chiara
    Celio, Luigi
    Mariani, Gabriella
    Bianchi, Giulia Valeria
    Capri, Giuseppe
    de Braud, Filippo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 139 : 53 - 66
  • [43] Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
    G Peiró
    F Ortiz-Martínez
    A Gallardo
    A Pérez-Balaguer
    J Sánchez-Payá
    J J Ponce
    A Tibau
    L López-Vilaro
    D Escuin
    E Adrover
    A Barnadas
    E Lerma
    British Journal of Cancer, 2014, 111 : 689 - 695
  • [44] Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
    Peiro, G.
    Ortiz-Martinez, F.
    Gallardo, A.
    Perez-Balaguer, A.
    Sanchez-Paya, J.
    Ponce, J. J.
    Tibau, A.
    Lopez-Vilaro, L.
    Escuin, D.
    Adrover, E.
    Barnadas, A.
    Lerma, E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (04) : 689 - 695
  • [45] Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment
    Ngamcherdtrakul, Worapol
    Castro, David J.
    Gu, Shenda
    Morry, Jingga
    Reda, Moataz
    Gray, Joe W.
    Yantasee, Wassana
    CANCER TREATMENT REVIEWS, 2016, 45 : 19 - 29
  • [46] Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
    Almstedt, Katrin
    Schmidt, Marcus
    BREAST CARE, 2015, 10 (03) : 168 - 172
  • [47] Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review
    Geng, Wujun
    Thomas, Holly
    Chen, Zhiyuan
    Yan, Zhixiu
    Zhang, Pujuan
    Zhang, Meiying
    Huang, Weixue
    Ren, Xiaomei
    Wang, Zhen
    Ding, Ke
    Zhang, Jinwei
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 977
  • [48] HER2DX: Advances in targeted treatment of HER2-positive breast cancer
    Andujar, Juan M. Cejalvo
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2024, 37 (03):
  • [49] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
    Diogo Mendes
    Carlos Alves
    Noémia Afonso
    Fátima Cardoso
    José Luís Passos-Coelho
    Luís Costa
    Sofia Andrade
    Francisco Batel-Marques
    Breast Cancer Research, 17
  • [50] Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma
    Curea, Fabiana G.
    Hebbar, Mohamed
    Ilie, Silvia M.
    Bacinschi, Xenia E.
    Trifanescu, Oana G.
    Botnariuc, Inga
    Anghel, Rodica M.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2017, 32 (10) : 351 - 363
12345